ℹ️
🇬🇧
Search
Search for publications relevant for "PI3K inhibitor"
PI3K inhibitor
Publication
Class
Person
Publication
Programmes
Export current view
publication
Alpelisib - the first PI3K inhibitor in the treatment of hormone-positive, HER2-negative breast cancer
2021 |
First Faculty of Medicine
publication
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
2023 |
Faculty of Medicine in Hradec Králové, First Faculty of Medicine
publication
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
2023 |
First Faculty of Medicine
publication
Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity
2019 |
Faculty of Medicine in Hradec Králové
publication
Alpelisib
2021 |
Third Faculty of Medicine
publication
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3
2019 |
Faculty of Pharmacy in Hradec Králové
publication
Protective Effect of Morphine Against the Oxidant-Induced Injury in H9c2 Cells
2018 |
Faculty of Science
publication
Treatment of HER2-positive breast cancer in 2020
2020 |
First Faculty of Medicine
publication
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells
2020 |
First Faculty of Medicine, Second Faculty of Medicine
publication
Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence
2021 |
First Faculty of Medicine, Second Faculty of Medicine